Perimenopause or early menopause — how to tell the difference, and why it matters.

They share many of the same symptoms. But they're biologically distinct, they unfold on different timelines, and the distinction shapes what your treatment options actually are. Here's how to read the signals clearly.

Why the confusion is so common — and so consequential

Women arrive at their GP or ob-gyn at 44 describing hot flashes, disrupted sleep, and cycles that are now 24 days, then 38 days, then 24 days again. The response they often receive is either "that sounds like menopause" or "your bloods look normal, it's probably stress." Both of these are frequently wrong, and the difference between them costs women months or years of appropriate care.

Perimenopause and early menopause are not the same thing. Perimenopause is a transition — a period that can span four to ten years during which ovarian function becomes increasingly erratic but has not ceased. Menopause is defined retrospectively as 12 consecutive months without a menstrual period, after which you are postmenopausal. "Early menopause" specifically means reaching that 12-month threshold before age 45. Premature ovarian insufficiency (POI), often still called premature menopause, means losing ovarian function before 40. These categories matter because they carry different risks, different treatment urgency, and different long-term implications — particularly for bone density and cardiovascular health.

The Study of Women's Health Across the Nation (SWAN), the largest longitudinal study of the menopause transition in the US, followed over 3,300 women through the transition and found the median age of the final menstrual period to be 51.4 years. But the perimenopausal transition leading to that point averaged 4–8 years in length, with significant individual variation. A woman experiencing classic perimenopausal symptoms at 44 may have many years of transition ahead of her — a very different clinical picture from a woman who has already been period-free for eight months at 43.

What FSH actually tells you — and what it doesn't

Follicle-stimulating hormone (FSH) is the pituitary's signal to the ovaries to produce follicles. As ovarian reserve declines, the pituitary pumps out more FSH trying to get a response. A persistently elevated FSH — typically defined as above 25–30 IU/L on two separate measurements at least one month apart — in the context of amenorrhoea (absent periods) is the primary laboratory criterion for diagnosing menopause or POI.

But here's what makes this genuinely tricky in perimenopause: FSH fluctuates enormously from cycle to cycle during the transition. In early perimenopause, you can have an FSH of 45 IU/L one month and 12 IU/L the next, because ovarian function is erratic rather than absent. A single elevated FSH reading in a woman who is still having occasional periods is not diagnostic of menopause. The SWAN data showed that FSH variability in late perimenopause can span more than 30 IU/L within the same individual across consecutive months.

Reading your cycle — the most underused diagnostic tool

The STRAW+10 staging system (Stages of Reproductive Aging Workshop), published in Menopause (Harlow et al., 2012) and updated with international consensus, provides the clearest framework for understanding where you are in the transition. It defines stages by cycle characteristics, not just symptoms:

• Early perimenopause: cycles that vary by 7 or more days from your normal, at least two such cycles in a row.
• Late perimenopause: 60 or more days since your last period — you're in the long-gap territory where the final period may not be far off.
• Menopause: 12 consecutive months without a period (confirmed retrospectively).

The clinical importance of tracking your cycle carefully cannot be overstated. A woman in early perimenopause who still ovulates occasionally can still conceive — and many don't know this. Equally, a woman in late perimenopause who has had two periods in the past year may assume she has years left; statistically, she's close to her final period. Cycle tracking apps and paper charting provide data that a single GP visit cannot replicate.

When "early menopause" requires a different response

If you reach the 12-month amenorrhea threshold before age 45, that's early menopause by definition, and the clinical picture changes meaningfully. A 2019 review in The Lancet (Mishra et al.) estimated that women who experience menopause before 45 have a roughly 50% higher risk of ischaemic heart disease and stroke compared to those who reach menopause at the population average — independent of other cardiovascular risk factors. The mechanism involves the accelerated loss of estrogen's vasodilatory and lipid-modulating effects.

For bone health, the numbers are similarly unambiguous. Estrogen is the primary brake on osteoclast activity — the cells that break down bone. Early menopause at 42 compared to average menopause at 51 represents an additional nine years of accelerated bone resorption without hormonal protection. The Framingham Osteopors2is Study showed that women with earlier menopause had meaningfully lower hip bone mineral density compared to those with later menopause, with effects on fracture risk persisting into their 70s.

This is why the major guidelines from the British Menopause Society and the Menopause Society (formerly NAMS) both recommend that women with early menopause — not just POI — be counselled about HRT until at least the average age of natural menopause (approximately 51), unless there are specific contraindications. The risk-benefit calculus for a 43-year-old starting HRT is fundamentally different from that of a 55-year-old, because the baseline risk of untreated estrogen deficiency is substantially higher in the younger woman.

The symptom overlap that misleads everyone

Hot flashes, night sweats, sleep disruption, mood volatility, brain fog, reduced libido — these symptoms are shared by perimenopause, early menopause, and POI. They're also shared by thyroid dysfunction, anaemia, and generalised anxiety disorder. The mistake made in too many consultations is treating symptoms alone without establishing what stage of ovarian function is driving them.

If you're 43 with hot flashes and a 28-day cycle, you're almost certainly perimenopausal, and your ovaries are still active. The treatment approach should account for the fact that estrogen levels are not uniformly low — they're oscillating chaotically, often hitting supraphysiological highs before crashing, which is why some perimenopausal women feel worse, not better, on standard HRT doses designed for postmenopausal estrogen deficiency.

If you're 43 and haven't had a period in seven months, the calculus is different. Two FSH measurements above 40 IU/L at least four weeks apart, with no period, is consistent with POI and requires investigation of causes (autoimmune, chromosomal, iatrogenic from chemotherapy or surgery) — not just symptomatic management. The evidence base for HRT in POI is about replacing what should still be there biologically, not about managing the symptoms of normal aging.

Ask your clinician to stage you, not just treat you. The staging tools exist. The hormonal tests exist. The distinction between perimenopause and early menopause changes what you should know about your long-term health, not just how you feel this week.